Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$81.18B+126.41%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Erez Israeli
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 27,527
- Beta
- 0.25
- Country
- IN
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 5.12
Financials
Revenue
$81.18B+126.4%Net Income
$4.46B+51.2%EBITDA
$2.97B-52.3%Free Cash Flow
$-4.63BEPS (diluted)
$5.35-69.9%Shares Outstanding (diluted)
832.67M+0.3%Operating Expenses
$34.79BCash & Debt
$81.43BReturn of Capital
$0.00Dividend per Share
$0.08Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $353.47B | $45.09B | $53.92 |
| 2025 | $325.54B | $56.54B | $67.85 |
| 2024 | $279.16B | $55.68B | $66.80 |
| 2023 | $245.88B | $45.07B | $54.29 |
| 2022 | $214.39B | $23.57B | $28.42 |
| 2021 | $2.56B | $232.21M | $20.79 |
| 2020 | $174.60B | $19.50B | $117.63 |
| 2019 | $153.85B | $18.80B | $113.28 |
| 2018 | $142.03B | $9.81B | $59.13 |
| 2017 | $140.81B | $12.04B | $72.24 |
| 2016 | $154.71B | $20.01B | $117.34 |
| 2015 | $148.19B | $22.18B | $130.22 |
| 2014 | $132.17B | $21.51B | $126.52 |
| 2013 | $116.27B | $16.78B | $98.82 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from RDY's reported EPS growth of -4.6% a year over 13 years.
- EPS in 5 years
- $42.80
- Implied price
- $1,027
- Return from $12.30
- 142.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $510.72 — today's price is already 97.6% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 20 | 24 | 28 | 32 |
|---|---|---|---|---|---|
| -14.6% | 100.0% | 109.1% | 116.9% | 123.7% | 129.7% |
| -9.6% | 111.7% | 121.4% | 129.6% | 136.8% | 143.2% |
| -4.6% | 123.4% | 133.6% | 142.3% | 149.9% | 156.6% |
| 0.4% | 135.1% | 145.9% | 155.0% | 163.0% | 170.1% |
| 5.4% | 146.8% | 158.1% | 167.7% | 176.1% | 183.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
140+600.00%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·5h ago·Neutral
Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·10h ago·Negative
Dr. Reddy's Laboratories Q2 Earnings Call Highlights Dr. Reddy's Laboratories NYSE: RDY reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset growth in its underlying business.
View source ↗ - Newsreuters.com·36d ago·Negative
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India Dr Reddy's Laboratories said on Friday it signed a deal with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.
View source ↗ - Newsbusinesswire.com·65d ago·Negative
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON DR. REDDY'S LABORATORIES (RDY), CLICK HERE …
View source ↗
Earnings
Fri, Oct 23(date passed)
Consensus estimate $0.10 per share
Typical surprise +5.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 21$0.06 vs $0.09miss
- Mon, May 11$0.06 vs $0.09miss
- Tue, Jan 20$0.16 vs $0.16beat
- Fri, Oct 24$0.19 vs $0.18beat
- Wed, Jul 23$0.20 vs $0.18beat
- Fri, May 9$0.22 vs $0.20beat
Estimates and results for RDY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RDY officers and directors.
No open-market trades in the recent filings. All 22 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
22 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RDY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.